A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

NCT01897116 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Hydroxychloroquine (HCQ)
DRUG: Vemurafenib (VEM)

Sponsor

Abramson Cancer Center at Penn Medicine